Cagdas Boyvadoglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Cagdas Boyvadoglu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Huseyin Serhat Inaloz
Department of Dermatology, Faculty of Medicine, Gaziantep University, 27410 Gaziantep, Turkey
3 shared publications - Goknur Ozaydin-Yavuz
Department of Dermatology and Venerology, Başakşehir Çam and Sakura City Hospital, Health Sciences University, 34480 Istanbul, Türkiye
2 shared publications - Ibrahim Halil Yavuz
Department of Dermatology, Başakşehir Çam and Sakura City Hospital, 34480 İstanbul, Türkiye
2 shared publications Ayse Serap Karadag
1 shared publication- Bahadir Aslancan
Department of Dermatology and Venereology, Şanlıurfa Training and Research Hospital , Şanlıurfa
1 shared publication Cagla Boyvadoglu
1 shared publication
Latest Publications
- Open Access
- 7 November 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (6)
The association of subjective quality of life with emotion dysregulation and binge-eating pathology in acne vulgaris: a cross-sectional study
- 7 November 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (6)
Open AccessThe association of subjective quality of life with emotion dysregulation and binge-eating pathology in acne vulgaris: a cross-sectional study
- 14 September 2026
- Published by Necmettin Erbakan University in Selcuk Tip Dergisi
Cutaneous Symptoms Observed in Patients Hospitalized in Gastroenterology Service: A 207-Case Single-Center Study
Amaç: Gastroenterolojik hastalık nedeniyle yatırılan ve dermatoloji konsültasyonu gerektiren erişkin hastalarda saptanan kutanöz bulguların dağılımını ve klinik özelliklerini değerlendirmek. Gereç ve Yöntemler: Bu tek merkezli, prospektif, kesitsel tanımlayıcı çalışmada, Eylül 2022 ile Eylül 2023 arasında Gaziantep Üniversitesi Tıp Fakültesi Gastroenteroloji Servisi’nde yatan ve dermatolojik bulgusu bulunan erişkin hastalar değerlendirildi. Demografik veriler, mevcut gastroenterolojik tanı, kullanılan ilaçlar, deri semptomları, lezyonların yerleşimi, morfolojisi, süresi ve dermatolojik tanıları kaydedildi. Tanılar öykü ve dermatolojik muayene temelinde konuldu; gerekli olgularda KOH ile direkt mikroskobik inceleme, yara kültürü ve histopatolojik inceleme kullanıldı. Veriler tanımlayıcı olarak sunuldu. Bulgular: Çalışmaya 207 hasta dahil edildi (107 erkek [%51,69] ve 100 kadın [%48,31]; ortalama yaş 54,30 ± 18,75 yıl). En sık altta yatan tanılar pankreas hastalıkları (%26,09), hepatobiliyer hastalıklar (%23,67), karaciğer sirozu (%19,81), gastrointestinal malignite (%16,43) ve inflamatuvar bağırsak hastalığı (%8,21) idi. En sık kutanöz bulgular kaşıntı (%60,38), başlıca ikter veya solukluk şeklinde renk değişikliği (%56,52), kserozis kutis (%45,41), hiperkeratotik değişiklikler (%43,47) ve enfeksiyonlar (%35,26) olarak saptandı. Sonuç: Gastroenteroloji servisinde yatan hastalarda dermatolojik bulgular geniş bir klinik yelpaze göstermektedir. Bu konsültasyon temelli seçilmiş kohortta kaşıntı, renk değişikliği ve kserozis öne çıkmıştır. Bulgular, gastroenteroloji servislerinde kutanöz semptomu olan hastalarda dermatolojik değerlendirmenin önemini desteklemekle birlikte, tüm gastroenteroloji hastaları için prevalans verisi olarak yorumlanmamalıdır.
- 14 September 2026
- Published by Necmettin Erbakan University in Selcuk Tip Dergisi
Cutaneous Symptoms Observed in Patients Hospitalized in Gastroenterology Service: A 207-Case Single-Center Study
Amaç: Gastroenterolojik hastalık nedeniyle yatırılan ve dermatoloji konsültasyonu gerektiren erişkin hastalarda saptanan kutanöz bulguların dağılımını ve klinik özelliklerini değerlendirmek. Gereç ve Yöntemler: Bu tek merkezli, prospektif, kesitsel tanımlayıcı çalışmada, Eylül 2022 ile Eylül 2023 arasında Gaziantep Üniversitesi Tıp Fakültesi Gastroenteroloji Servisi’nde yatan ve dermatolojik bulgusu bulunan erişkin hastalar değerlendirildi. Demografik veriler, mevcut gastroenterolojik tanı, kullanılan ilaçlar, deri semptomları, lezyonların yerleşimi, morfolojisi, süresi ve dermatolojik tanıları kaydedildi. Tanılar öykü ve dermatolojik muayene temelinde konuldu; gerekli olgularda KOH ile direkt mikroskobik inceleme, yara kültürü ve histopatolojik inceleme kullanıldı. Veriler tanımlayıcı olarak sunuldu. Bulgular: Çalışmaya 207 hasta dahil edildi (107 erkek [%51,69] ve 100 kadın [%48,31]; ortalama yaş 54,30 ± 18,75 yıl). En sık altta yatan tanılar pankreas hastalıkları (%26,09), hepatobiliyer hastalıklar (%23,67), karaciğer sirozu (%19,81), gastrointestinal malignite (%16,43) ve inflamatuvar bağırsak hastalığı (%8,21) idi. En sık kutanöz bulgular kaşıntı (%60,38), başlıca ikter veya solukluk şeklinde renk değişikliği (%56,52), kserozis kutis (%45,41), hiperkeratotik değişiklikler (%43,47) ve enfeksiyonlar (%35,26) olarak saptandı. Sonuç: Gastroenteroloji servisinde yatan hastalarda dermatolojik bulgular geniş bir klinik yelpaze göstermektedir. Bu konsültasyon temelli seçilmiş kohortta kaşıntı, renk değişikliği ve kserozis öne çıkmıştır. Bulgular, gastroenteroloji servislerinde kutanöz semptomu olan hastalarda dermatolojik değerlendirmenin önemini desteklemekle birlikte, tüm gastroenteroloji hastaları için prevalans verisi olarak yorumlanmamalıdır.
- 28 March 2024
- Published by Springer Nature in Current Dermatology Reports
- Vol. 13 (2) , 115-122
Symmetrical Drug-Related Intertriginous and Flexural Exanthem-Like Eruption Post-COVID-19 Vaccination: A Case Report and Review of the Literature
- 28 March 2024
- Published by Springer Nature in Current Dermatology Reports
- Vol. 13 (2) , 115-122
Symmetrical Drug-Related Intertriginous and Flexural Exanthem-Like Eruption Post-COVID-19 Vaccination: A Case Report and Review of the Literature
- Open Access
- 26 September 2023
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-6
Effects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria
The mechanism of action of omalizumab in urticaria is still not literally known. This study examines the serum values of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and interleukin-31 (IL-31) in patients using omalizumab. In this study, 30 patients with chronic spontaneous urticaria (CSU) who were going to be treated with omalizumab and 20 healthy volunteers took part. Demographic data, clinical data, and disease activity scores were noted. For serum SP, CGRP, NPY, and IL-31 values, 10 mL of blood were taken from the patients before starting the treatment, 3 months after the treatment, at the end of the 6th month, and from healthy volunteers all at once. The change in values measured at baseline, 3rd month, and 6th month was analyzed by the Friedman Test. The Mann–Whitney U test was used to compare the parameters obtained from the patients and control groups. The significance level was set at . SP, CGRP, NPY, and IL-31 values were all statistically significantly lower in the CSU patient group compared to the control group. After treatment, the levels of SP and CGRP in the serum went up, and the levels of serum IL-31 went down. These changes were statistically significant. This study supports the view that omalizumab does not only affect IgE receptors but also affects mast cells through other mechanisms. According to our knowledge, this is the first study to show that omalizumab therapy and serum CGRP levels are related.
- 26 September 2023
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-6
Open AccessEffects of Omalizumab on Serum Levels of Substance P, Calcitonin Gene-Related Peptide, Neuropeptide Y, and Interleukin-31 in Patients with Chronic Spontaneous Urticaria
The mechanism of action of omalizumab in urticaria is still not literally known. This study examines the serum values of substance P (SP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and interleukin-31 (IL-31) in patients using omalizumab. In this study, 30 patients with chronic spontaneous urticaria (CSU) who were going to be treated with omalizumab and 20 healthy volunteers took part. Demographic data, clinical data, and disease activity scores were noted. For serum SP, CGRP, NPY, and IL-31 values, 10 mL of blood were taken from the patients before starting the treatment, 3 months after the treatment, at the end of the 6th month, and from healthy volunteers all at once. The change in values measured at baseline, 3rd month, and 6th month was analyzed by the Friedman Test. The Mann–Whitney U test was used to compare the parameters obtained from the patients and control groups. The significance level was set at . SP, CGRP, NPY, and IL-31 values were all statistically significantly lower in the CSU patient group compared to the control group. After treatment, the levels of SP and CGRP in the serum went up, and the levels of serum IL-31 went down. These changes were statistically significant. This study supports the view that omalizumab does not only affect IgE receptors but also affects mast cells through other mechanisms. According to our knowledge, this is the first study to show that omalizumab therapy and serum CGRP levels are related.
- 13 September 2023
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (12) , E612-E614
Rituximab‐induced mucosal pyogenic granuloma
- 13 September 2023
- Published by Wiley in International Journal of Dermatology
- Vol. 62 (12) , E612-E614
Rituximab‐induced mucosal pyogenic granuloma
- 20 June 2022
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (6) , 2858-2861
Omalizumab is not just an anti-immunoglobulin E
The mechanism of omalizumab in urticaria is not literally known. Omalizumab may affect receptors on the mast cell surface in other ways, especially other than Fc epsilon RI.Thirty patients who were...
- 20 June 2022
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 33 (6) , 2858-2861
Omalizumab is not just an anti-immunoglobulin E
The mechanism of omalizumab in urticaria is not literally known. Omalizumab may affect receptors on the mast cell surface in other ways, especially other than Fc epsilon RI.Thirty patients who were...